Structure Encountered

Violet Therapeutics

Develops CNS therapeutics using proprietary cell-to-cell interaction discovery platform

Violet adds $4.75M to its seed for an EphB3 program built off the CONNECT cell-to-cell platform. Dementia Discovery Fund, UTEC, Ono, and MGB Ventures all re-up. Lifespan Vision Ventures leads.

SIGNAL·Seed extension financing·$4.75M seed extension·SCORE 72·19 MAY 2026 · 12:47 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

Structure Violet Therapeutics, captured by Voyager

STRUCT. / VIOLET THERAPEUTICS

/ United States

CAPT. / 19.05.26 12:47:05Z

SIGNAL / 72 / 100

Image relayed by The Biotech Voyager during pass over structure Violet Therapeutics. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Violet Therapeutics

Coordinates

United States

Stage

Preclinical

Type

Therapeutics

Modalities

small molecule

Therapeutic area

Cns · Neurology

002Signature Detected

FUNDING EVENT

Event type

Seed extension financing

Magnitude

$4.75M seed extension

Lead investor

Lifespan Vision Ventures

Participating

Dementia Discovery Fund, UTEC, Ono Venture Investment, Mass General Brigham Ventures

Use of capital

Not explicitly disclosed; brings total seed to ~$15.35M and supports continued advancement of the preclinical EphB3 inhibitor program toward IND and additional CONNECT-derived targets.

003Architecture

PLATFORM PROFILE

Target class

EphB3 receptor tyrosine kinase (mediates microglia-astrocyte crosstalk in neuroinflammation)

Differentiator

CONNECT platform (also called C-to-C Engine, built on RABID-Seq barcoded viral tracing) maps cell-cell crosstalk at single-cell resolution. EphB3 was previously a developmental axon guidance target; Violet's platform pulled it out as the receptor driving microglia-astrocyte signaling in pathological neuroinflammation. Most Alzheimer's programs hit amyloid or tau. Violet is going one layer deeper, at the glial communication that drives synapse loss.

Lead asset

Small molecule EphB3 inhibitor (preclinical) for glial-mediated synaptic preservation in Alzheimer's disease

Pipeline depth

Single disclosed preclinical lead: small molecule EphB3 inhibitor. Platform (CONNECT / C-to-C Engine, with RABID-Seq, FIND-seq, SPEAC-seq) is also being applied beyond CNS to inflammation, oncology, and barrier-tissue diseases.

004Voyager Assessment

MACHINE-GENERATED

A $4.75M seed extension is small, but the syndicate is signal. Dementia Discovery Fund, UTEC, Ono, and Mass General Brigham Ventures all re-up while Lifespan Vision Ventures comes in to lead. That tells you the existing backers still believe the EphB3 thesis after three years of preclinical work. The interesting question for the next round is whether CONNECT has surfaced a second target. A platform company that ships one program is a one-trick pony. A platform that ships three is a real platform. Watch for the second program disclosure.

005Adjacent Structures

FRONTIER MAP

Abelian Therapeutics· glial-targeted Alzheimer's (acquired by Neumora)ABLi Therapeutics· small molecule LRRK2 neurodegenerationTenvie Therapeutics· CNS-penetrant NLRP3 neuroinflammationNeuroTherapia· oral small molecule neuroinflammation in ADKorsana Biosciences· BBB-shuttled anti-amyloid antibodyAC Immune· misfolded protein precision medicineEisai/Biogen· Alzheimer's amyloid commercial standard

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.